{"name":"Kezar Life Sciences","slug":"kezar","ticker":"KZR","exchange":"NASDAQ","domain":"kezarlifesciences.com","description":"Kezar Life Sciences (KZR) is a biopharmaceutical company focused on developing treatments for autoimmune and inflammatory diseases. The company's pipeline includes several promising candidates, including zanubrutinib and zanubrutinib combination therapies. With a strong focus on research and development, Kezar Life Sciences aims to bring innovative treatments to patients in need. As a result, the company has established itself as a key player in the autoimmune and inflammation therapeutic area.","hq":"South San Francisco, CA","founded":0,"employees":"","ceo":"John F. Paolini","sector":"Autoimmune / Inflammation","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$145M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":33756000,"netIncome":-56033000,"cash":71878000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Zanubrutinib patent cliff ($0.0B at risk)","drug":"Zanubrutinib","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Kezar Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Kezar Life Sciences reported its fourth quarter and full year 2023 financial results, with a net loss of $44.8 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Kezar Life Sciences Announces Collaboration with Pfizer to Develop Zanubrutinib Combination Therapies","summary":"Kezar Life Sciences announced a collaboration with Pfizer to develop zanubrutinib combination therapies for the treatment of autoimmune and inflammatory diseases.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxNeHp3ejFjLWNiZWN5ZkN2Ty04dHExZkdUNEhqR0k4NU53OVhzZUxyTDBlbGtNb3hzc3lEQmZUTm9ZXzdTbEtWeFZfb0JQZjRMSjZrTi1NMmFHbUNEaFAtUldDVHZLLWdFb1FSX29RTE9TNndza2dRNkJMb2FIemQ1TFVUc0VYR202c2tPUlltd1l4S0JQYURWMVhneUIyNjhLMDJYdXZ2eXdsTldyQ2QwS3EzaHlEVHRpcUsxOTNIMUhjcEdUelhiSUZSZVZzMmZwUU5MTEV3VUI2Rzc1NVVmSlRqQ1ltRTFBLTlTOXNFUEN3cmJlQUFBTXhETnVNMFpwbm1QSWZCQXU2dWdsZ2tiWUloTmxPU0dZaVhRRS0wUWdvMjh5bnY1OHBzMENzbDVCeDk1aUFudVlCUTBq?oc=5","date":"2026-04-04","type":"pipeline","source":"MSN","summary":"Aurinia Pharmaceuticals acquiring Kezar Life Sciences - MSN","headline":"Aurinia Pharmaceuticals acquiring Kezar Life Sciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxNeGxyY1RrVHhDaC1MOXlOeG9CdVRrcXFHUEFzbG00R2xqX3dndHREVzEwUUlPMzh5dDh4aE5XbUZ0Z3VpLVlRNGozWGRBOENxcC1RY2FLMVhEenFWbXZIS3hiUzI5bXJGUmxuRDF5WmlhTExqclY3U05MRXNHajRwVUxxcXpncXg4VE1EQW1HdDZ0Tmp4RnlkQ0ZHdVJkck5XSzQ5X050cmsycTJuRk8yS2ltWmQ1N0NVZlg5SDlvRm12dWh5UTVxTE41enVaR1NHWG4wdzdOZjgydlBxVFhDbGotTnlaUDloZ0xNMkxnV055VlBsYXc?oc=5","date":"2026-04-04","type":"deal","source":"Minichart","summary":"Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.96 Per Share Plus Contingent Value Rights in 2026 Merger Deal - Minichart","headline":"Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.96 Per Share Plus Contingent Value Rights in 2026 Merger D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOVEdhYzR1U3ZLbHl2aXUxcWZJb2x3ckJDUVMyZ2lBWTEtY1pJSl8zWmVRYWtXWGEwblBNUTVnYlEwYlZmaWZINHVGTF94WkpfTVlKYm5UNk9HeU4yNXlpR3dQallDZ0lSSzFoem9PWXhLeC1UeFlkZk1rVGhONk9kR2J2NmNjSjh6SG14RE1FdGFKUVdYMm9GMFZmRC1DSHpwdF9VNVE4M2VNYUZqZlBZUQ?oc=5","date":"2026-04-03","type":"deal","source":"Stock Titan","summary":"Aurinia to acquire Kezar (NASDAQ: KZR) for $6.955 cash plus CVR - Stock Titan","headline":"Aurinia to acquire Kezar (NASDAQ: KZR) for $6.955 cash plus CVR","sentiment":"neutral"},{"date":"2026-04-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQZW45NVBZMVh2U2RUSVFhRjZaOS0xeWpmSHkyZzcwZ2wwejFPUkh2aHlGb212a0VxbzR5ZFB0UWQ4VlpjODN0SFZiWjlZTXU5d3Zjcy1GYnF2NmJTWElXcFJrWC1UUkUwTVJJMHFQeWNxRmVPQWtiek9VbW15ak5nYlZsTGxnTnNGVjlJ?oc=5","date":"2026-03-31","type":"deal","source":"The Pharma Letter","summary":"Aurinia to acquire Kezar Life Sciences - The Pharma Letter","headline":"Aurinia to acquire Kezar Life Sciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxNd2FMT1gwTUZwNldIUklCb0xmUURGc1JtQ2dZYXlaZG1vRzgyTzB5SFhfRVNzNFJzelp0Z0RsSzRIbTEzNlo1WWVZeFlYM2VPOVdaY2ttTWVONWp3OTFhYXg2ZXRES2lLN2c0Z09rV1ozTUNaTWVLQnd1djFZRzhuUG90YmdVSWl1SVJfanQxOVFmQTdoVmdNaHhuZUgxcGtZbnZwa1EwSTBrNGVIdzBLUVBmNFByQ3BEX2VxN0dfdUQ0Z1NoaVhoeFVUQ0lreThjcTIyRWpQZE5FMmpoa0JidVVrQXJ2b1JZNG5wQXQwaEFjcFVaaHl6cTFpbWo0YkpUUmc?oc=5","date":"2026-03-30","type":"deal","source":"Business Wire","summary":"Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right - Business Wire","headline":"Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNMDRwSC1pMkNFYXBDSGVmeXNSUmZwNU44S201TzhoM3pmTW96c0VYUmp2d2NXTU5QNHM5YVQxcmxyT2o5SGllcFJ1Ums4QjNNYUVvMS1Ia19laGJGWDBwRDBmVFlzc2NCZ3MyOFJxZldNbXlnd3RfdVlvT2F1Y1NNci1uWlNkYVNsRURJcC1IWnFZMjNRUzNXZG1mTC1uRzhscm1JQ1dqSHR0ancwRFI1bVgySQ?oc=5","date":"2026-03-30","type":"deal","source":"National Today","summary":"Aurinia Pharmaceuticals to Acquire Kezar Life Sciences - National Today","headline":"Aurinia Pharmaceuticals to Acquire Kezar Life Sciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxORXFpaGswTDJtWFF6RDljUFduT0QzUWs2QkxYZHRMRnV3S1NXa3BOWl9LUEtpVm1FRTJ6bk1XSl9CZUdxeUxxOV93NGFuMDNvUzAzZXdESHN4YWtZSHZLa2RneGJpbEQ5bGRWUUVBX1ZUYVRBc1FORlNzcXd3aHYzeUM3Wm4wR01CZzJlUnJLMlRJOTVIX2JmOE1LY0tVcjBSZWpSMzR2LTk0YXAyZW81ckZxQ3hEdGVFWGFwcHJabGFjNzZJdS1DUnlIamx1V3ZUNVJRVGJOS0tGU1E4UlpHQ2szajBYM1hXdHFoSHlRanNwUjJMaDgyYnhOcw?oc=5","date":"2026-03-30","type":"pipeline","source":"Morningstar","summary":"$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR) - Morningstar","headline":"$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxPanVHTHVhN3lSX0JqdXpZSHF3Y1pMYzJVYmNyZm02MzNBeUlXRzMxVGluOFl3YjFLNjJVdEZNS3NfZXVGOThCaTBkOEt3VWNQalF3eEhWTnhLcHprY3hGUW5jWklzWEtrMlhfcVJQZW1tMFRRWi15ZXNpb2lQeW5nRTh5azFZUHhyelhpemdRcUxjdk1YVW9FQ2hmMUZsTmZvbGF4a0RzTUJacG5FOTc2N3JNbGM5b0o4Z2hJOWVUQ0ZRRnFHdDRHOW1fT0NpRkRyNTc0eWJxYjQ3bl9SNkUwV1NJR002T3pBb2NhMUg1dHQ2QWRMUGlBczh0N0tKOGcyZjlDM1RvdU9aZkR3U2JUbU1EWmc?oc=5","date":"2026-03-30","type":"pipeline","source":"Business Wire","summary":"KZR Stock Alert: Halper Sadeh LLC is Investigating Whether Kezar Life Sciences, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire","headline":"KZR Stock Alert: Halper Sadeh LLC is Investigating Whether Kezar Life Sciences, Inc. is Obtaining a Fair Price for its S","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOZHJvbzZUWXF2TDRXRGVfRTBFc2s2bTRoUTZVZG1fanI4Z2x5VU1aZ3pSeEtPWWdIRlY1V1dsRUNRWnp6cEY5bGlMNjBWNVFfOFNKRGRLMXc4U3dpOFR4TWlMc19BbFAyNlItOHZ5R2lTWEx4X1p6SkdWb09aeU5aOXhDaWloQmg4OVB5ZGl5R1dyVWNVVkl2dkFJQzhPRkNFSHBpSm85ZlhPeGg5dWozRg?oc=5","date":"2026-03-30","type":"deal","source":"Stock Titan","summary":"Aurinia (NASDAQ: AUPH) to buy Kezar (NASDAQ: KZR) for $6.955 plus CVR - Stock Titan","headline":"Aurinia (NASDAQ: AUPH) to buy Kezar (NASDAQ: KZR) for $6.955 plus CVR","sentiment":"neutral"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-27","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE43dE5mLXoxVXF5ODItVXdYRFdocXpCUzNmRy11S1M5cVpjZ3RTT2ZTZ1RvaFFUSDNTMGZSanVWZklNN3VVME9QSnd4cW1kQkZlbl96S3JkVnQweTM0T05QY0E5Nk5iUDdwY0dlZw?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Kezar Life Sciences (KZR) - Stock Titan","headline":"If You Invested $1,000 in Kezar Life Sciences (KZR)","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5LSjdtT242eTYtRHRDVG13MFJUMWFrTmExVjZXZGFFbXZ4Y0RaeENULTdIZTZKQzZUb0U0MVhnSnB3VzRFRzFNaThCOGk4VUpDQlJB?oc=5","date":"2026-02-13","type":"earnings","source":"Intellectia AI","summary":"AUPH Stock News Today | Earnings, Events & Price Alerts - Intellectia AI","headline":"AUPH Stock News Today | Earnings, Events & Price Alerts","sentiment":"neutral"}],"patents":[{"drugName":"Zanubrutinib","drugSlug":"zanubrutinib","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Biogen","Regeneron Pharmaceuticals"],"therapeuticFocus":["Autoimmune Diseases","Inflammatory Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":0,"period":"2025-12-31"},{"value":0,"period":"2024-12-31"},{"value":7000000,"period":"2023-12-31"},{"value":0,"period":"2022-12-31"},{"value":0,"period":"2021-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":33756000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-56033000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":71878000,"cashHistory":[],"totalAssets":76647000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}